September 28, 2016
Otsuka Pharmaceutical Co., Ltd.
Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
- Mikeluna combination ophthalmic solution is an Otsuka-developed eye drop containing a combination of the non-selective β-blocker cartelol hydrochloride and the prostaglandin analogue latanoprost.
- Usually glaucoma is treated initially with a single therapeutic agent and if intraocular pressure is not controlled sufficiently then additional agents are prescribed. However, the requirement to wait between applications of each eye drop may reduce the efficacy of the treatment as dose adherence often decreases. A combination of the two into one formulation would improve adherence.
Otsuka Pharmaceutical Co., Ltd. on September 28, 2016 obtained regulatory approval in Japan for the manufacture and marketing of Mikeluna combination ophthalmic solution for glaucoma and intraocular hypertension. The drug will be co-promoted with Senju Pharmaceutical Co., Ltd.
Information in this news release was current as of the original release date.